According to NPPA, of the 1,01,418 pharma stock keeping units observed, prices of 4,724 SKUs were found to have changed beyond permissible limit as per DPCO 2013.
It further said prices of 17,226 SKUs rose within the permissible limit as per as DPCO 2013. While prices of 18,104 SKUs declined, there was no change in those of 60,998 SKUs as per the study conducted by NPPA in August last year.
NPPA found that 95.4 per cent of SKUs complied with the DPCO, 2013 from pricing perspective.
Комментариев нет:
Отправить комментарий